Skip to main content
SpringerLink
Log in

Response to upadacitinib in a patient with palmoplantar psoriasis

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol 2022; 87: 784–91.

    Article  CAS  PubMed  Google Scholar 

  2. Garcia-Melendo C, Cubiró X, Puig L. Janus kinase inhibitors in dermatology: part 2: applications in psoriasis, atopic dermatitis, and other dermatoses. Actas Dermosifiliogr (Engl Ed) 2021; 112: 586–600.

    Article  CAS  PubMed  Google Scholar 

  3. Sarabia S, Ranjith B, Koppikar S, et al. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol 2022; 6: 71.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol 2016; 17: 349–58.

    Article  PubMed  Google Scholar 

  5. Sanchez IM, Sorenson E, Levin E, et al. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. Dermatol Ther (Heidelb) 2017; 7: 425–46.

    Article  PubMed  Google Scholar 

  6. Burmester GR, Winthrop K, Blanco R, et al. Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal Phase 3 trials. Rheumatol Ther 2022; 9: 521–39.

    Article  PubMed  Google Scholar 

  7. Akpabio A, Adebajo A. Evaluating upadacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother 2022; 23: 169–73.

    Article  CAS  PubMed  Google Scholar 

  8. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signalling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183: 3170–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Funding: none.

Author information

Authors and Affiliations

  1. Department of Dermatology, Hospital University Germans Trias i Pujol, Badalona, Autonomous University of Barcelona, Barcelona, Spain

    Manel Martinez-Molina, Juan José Lluch-Galcerá & José Manuel Carrascosa

Authors
  1. Manel Martinez-Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan José Lluch-Galcerá
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Manuel Carrascosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manel Martinez-Molina.

Ethics declarations

Conflicts of interest: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martinez-Molina, M., Lluch-Galcerá, J.J. & Carrascosa, J.M. Response to upadacitinib in a patient with palmoplantar psoriasis. Eur J Dermatol 33, 301–302 (2023). https://doi.org/10.1684/ejd.2023.4489

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2023.4489

Search

Navigation